{
  "docId": "019de072-7463-7169-8f31-7c4d89e9eac4",
  "docSlug": "d88eea3c6872c4e67cae911eb0680043",
  "documentTitle": "argenx SE | Results Presentation Deck | 10 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 10,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a biological process diagram showing the interaction between Efgartigimod, FcRn, and IgG in an endothelial cell.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7463-7169-8f31-7c4d89e9eac4/3",
  "deckHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4",
  "deckJsonHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4.json",
  "deckAnchorHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.48,
        "x": 0.48,
        "y": 0.15
      },
      "kind": "image",
      "text": "Biological diagram of FcRn recycling pathway and Efgartigimod mechanism",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "292c2e74-2186-41b7-9095-d24dfd5191c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "Targeted reduction of all IgG subtypes; No impact on IgM or IgA; No reduction in albumin levels; No increase in cholesterol",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6285f18-add9-49c4-881b-cbb27322bfaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "FcRn recycles IgG, extending its half-life and serum concentration. Efgartigimod is a human IgG1 Fc fragment, a natural ligand of FcRn, engineered for increased affinity to FcRn. Efgartigimod was designed to outcompete endogenous IgG.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2d631b6-9da5-4d15-857c-e1f332ba81da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Image adapted from Kang TH, Jung ST. Exp Mol Med. 2019;51(11):1-9. References 1-5.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dc2b674-ac2b-409d-9a88-ce4a6d100b0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Efgartigimod Mechanism of Action: Blocking FcRn",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b024f5dd-e14a-483c-b555-f0bd47163936",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 2,
      "beatId": "438cbf55-8155-4d46-a46c-b3e3342ff915",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problem by showing the need for better therapies and the limitations of current treatments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}